Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X

J Am Coll Cardiol. 1998 Jun;31(7):1585-90. doi: 10.1016/s0735-1097(98)00143-0.

Abstract

Objectives: This study sought to assess the contribution and action of nitric oxide and endothelin-1 in peripheral resistance vessels of patients with syndrome X.

Background: Patients with syndrome X may have a generalized disorder of vascular and endothelial function, promoting vasospasm.

Methods: Changes in blood flow responses to intrabrachial infusion of the endothelium-dependent vasodilators substance P and acetylcholine, the endothelium-independent nitric oxide donor sodium nitroprusside and the endothelin type A (ET(A)) receptor antagonist BQ-123 were assessed using venous occlusion plethysmography in 10 patients with syndrome X and 10 matched control subjects. Vasoconstrictor responses to the nitric oxide synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA) and endothelin-1 were also determined.

Results: There were no significant differences in the responses to acetylcholine, substance P, sodium nitroprusside or BQ-123 between patients and control subjects. However, despite similar degrees of vasoconstriction in response to L-NMMA in both groups, endothelin-1 caused a reduction in forearm blood flow of only 20 +/- 2% in patients with syndrome X compared with 35 +/- 3% in matched control subjects at 90 min (p < 0.001). Although plasma endothelin-1 concentrations were not significantly higher in patients with syndrome X (4.8 vs. 4.0 pg/ml, p = 0.17), the vasoconstriction caused by endothelin-1 infusion correlated inversely with plasma endothelin-1 concentrations (r = -0.51, p = 0.04).

Conclusions: Patients with syndrome X had normal basal and stimulated nitric oxide activity and basal endogenous ET(A) receptor-mediated vascular tone. However, despite otherwise normal vascular function, there was reduced responsiveness to exogenous endothelin-1, possibly reflecting overactivity of this system and ET(A) receptor downregulation.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Endothelin Receptor Antagonists
  • Endothelin-1 / blood
  • Endothelin-1 / physiology*
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Male
  • Microvascular Angina / physiopathology*
  • Middle Aged
  • Nitric Oxide / physiology
  • Nitroprusside / pharmacology
  • Peptides, Cyclic / pharmacology
  • Regression Analysis
  • Vascular Resistance*
  • Vasodilator Agents / pharmacology
  • omega-N-Methylarginine / pharmacology

Substances

  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Enzyme Inhibitors
  • Peptides, Cyclic
  • Vasodilator Agents
  • Nitroprusside
  • omega-N-Methylarginine
  • Nitric Oxide
  • cyclo(Trp-Asp-Pro-Val-Leu)